Court rejects Novo bid to block Lilly obesity drug ads
Novo failed to prove that Lilly’s campaign — which featured claims of obesity drug superiority — meaningfully harmed the Danish company’s sales, a federal judge ruled.
Novo failed to prove that Lilly’s campaign — which featured claims of obesity drug superiority — meaningfully harmed the Danish company’s sales, a federal judge ruled.